Sageworth Trust Co Buys Shares of 10,000 Mesoblast Limited (NASDAQ:MESO)

Sageworth Trust Co purchased a new position in shares of Mesoblast Limited (NASDAQ:MESO) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 10,000 shares of the company’s stock, valued at approximately $198,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MESO. Strategic Financial Concepts LLC acquired a new position in Mesoblast during the fourth quarter worth $2,744,000. XY Capital Ltd bought a new stake in Mesoblast during the 3rd quarter worth about $244,000. Jane Street Group LLC boosted its stake in shares of Mesoblast by 46.4% during the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after buying an additional 26,959 shares during the last quarter. Creative Planning bought a new position in shares of Mesoblast in the 3rd quarter valued at about $147,000. Finally, Clayton Financial Group LLC acquired a new position in shares of Mesoblast during the 4th quarter worth approximately $275,000. 1.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on MESO shares. Jefferies Financial Group cut shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. Piper Sandler restated an “overweight” rating and issued a $24.00 price objective (up previously from $15.00) on shares of Mesoblast in a research note on Friday. Finally, Cantor Fitzgerald upgraded Mesoblast to a “strong-buy” rating in a research note on Thursday, January 30th. One analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Mesoblast Price Performance

Mesoblast stock opened at $19.49 on Friday. Mesoblast Limited has a twelve month low of $1.75 and a twelve month high of $22.00. The company’s 50-day moving average price is $16.33 and its two-hundred day moving average price is $10.92. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.